Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a dose finding study using a 3 + 3 dose escalation and expansion design to determine
a Not Tolerated Dose (NTD), Optimal Biological Effect Dose (OBE) and / or Maximum Tolerated
Dose (MTD). These data will be used to establish a Recommended Phase 2 Dose (RP2D) for the
combination of CC-292 and Rituximab in subjects with CLL.